Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

RMC-6291 is a covalent inhibitor of KRAS containing a glycine-to-cysteine mutation at position 12 (KRASG12C).1 It binds to KRASG12C and prevents KRASG12C-induced signaling via recruitment of peptidyl-prolyl cis-trans isomerase A (PPIase A), also known as cyclophilin A (CypA). It decreases the proliferation of 15 cancer cell lines expressing KRASG12C (median EC50 = 0.11 nM) and induces apoptosis in NCI H358 non-small cell lung cancer (NSCLC) cells. RMC-6291 (10-200 mg/kg per day) reduces tumor volume in an NCI H358 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science 381(6659), 794-799 (2023).